Role of multi-detector row CT angiography in the management of gastric fundal varices

We read with great interest the article by Willmann et al (Gut 2003;52:886–92) regarding the superiority of multi-detector row CT (MDCT) angiography over endoscopic ultrasound for the detection and characterisation of submucosal gastric fundal varices (FV). We strongly agree that MDCT angiography provides excellent visualisation of FV, as well as afferent and efferent veins, and that it provides valuable anatomical information for deciding the therapeutic strategies for FV (fig 1A, B).1,2

Iwase and colleagues3 divided FV into localised and diffuse types using MDCT angiography. This classification resembles the findings obtained by investigation of resected or autopsied stomachs.4 According to Iwase and colleagues,5 diffuse FV are more difficult to obliterate with cyanoacrylate than localised FV. Diffuse FV may be better treated with balloon occluded retrograde transvenous obliteration (B-RTO).6

Although FV with a high risk of bleeding have not yet been fully clarified, they are defined according to the criteria proposed by Kim and colleagues7 in Japan. Because high risk FV are easily detected endoscopically, they are not necessary to distinguish FV from perigastric collateral veins by MDCT angiography.

MDCT angiography can also provide useful information for evaluation of the effect of treatment of FV.8 Obliteration of the afferent veins as well as the actual varices is important to prevent recurrence.9 If these vessels are not visualised by MDCT angiography after therapy, FV will rarely recur.10 With regard to the treatment of FV reported by the authors, we also have some comments. Firstly, they treated a patient by transjugular intrahepatic portosystemic shunting (see fig 2 in Willmann et al). However, as the patient had a type 2 portal haemodynamic pattern, as classified by Kanagawa and colleagues,11 B-RTO would have been preferable if his portal pressure gradient was less than 12 mm Hg.12 Second, we would like to ask the authors how they treated the patient presented in fig 3? As the varices seem to be so-called GOV2, as classified by Sarin and Kumar,13 they could be treated by endoscopic sclerotherapy with the oesophageal varices.

A Matsumoto, Y Sugano, M Yasuda, K Takimoto Takeda General Hospital, 28-1 Ishida Marimintadi-cho, Fushimi, Kyoto, Japan

Correspondence to: Dr A Matsumoto; marash@tkgh.odn.ne.jp

References

Authors’ reply
We thank Dr Matsumoto et al for their interest in our work.

Balloon occluded retrograde transvenous obliteration (B-RTO) is a recently described interventional radiology technique which allows effective treatment of gastric varices, similar to but less invasive than transjugular intrahepatic portosystemic shunt stent (TIPSS).5 It has recently been shown that B-RTO of gastric varices can even be performed through the left inferior phrenic vein which represents the efferent vein of gastric varices.2 There is no doubt that B-RTO through the left inferior phrenic vein would have been an option for the treatment of the patient shown in fig 2 of our article (Gut 2003;52:886–92). However, since the portal venous pressure gradient in this particular patient was 28 mm Hg, we preferred to place a 10 mm diameter TIPSS in this particular patient.

The patient illustrated by fig 3 in our study (Gut 2003;52:886–92) was classified as having gastro-oesophageal varices type 2 (GOV-2), according to the endoscopic classification proposed by Sarin and Kumar.13 This patient underwent endoscopic sclerotherapy.

J K Willmann, D Weishaupt, T Böhm, T Pfammatter Institute of Diagnostic Radiology, University Hospital, Zurich, Switzerland

P Bauerfeind Division of Gastroenterology, University Hospital, Zurich, Switzerland

Correspondence to: Dr D Weishaupt, Institute of Diagnostic Radiology, University Hospital, Rämistrasse 100, 8091 Zurich, Switzerland; dominik.weishaupt@dnr.usz.ch

References
Primary antiphospholipid syndrome as a new cause of autoimmune pancreatitis

I read with interest the article by Kamisawa et al regarding the aetiology of autoimmune pancreatitis (Gut 2003;52:683–7). The cause of a significant proportion of cases of acute pancreatitis remains uncertain. I would like to describe a case of acute pancreatitis associated with antiphospholipid syndrome to highlight another potentially important cause of autoimmune pancreatitis which I believe has not been previously described.

Case report

A 30 year old woman was admitted twice in the space of three months with acute pancreatitis. She had a past medical history of anxiety and occasional migraines, for which she took alprazolam and propranolol, respectively. She had suffered two miscarriages and had one healthy child. She drank 3 units of alcohol per day. She was otherwise well and had no history of musculoskeletal problems.

On both occasions her amylase level was significantly elevated (787 and 364, respectively). Ultrasound and computed tomography of her abdomen were carried out each time and demonstrated a diffusely swollen pancreas consistent with acute pancreatitis, but with no evidence of gall stones or biliary duct dilatation. Liver function tests were all normal with the exception of a slightly elevated gamma glutamyl transferase level. Glucose, lipids, thyroid stimulating hormone, calcium, and clotting (international normalised ratio and activated partial thromboplastin time) were all normal. Full blood count was normal except for a neutrophilia during her acute illness. Her erythrocyte sedimentation rate was raised at 78. Urine microscopy and urinary protein excretion were both normal. On her second admission to hospital she had four generalised seizures and magnetic resonance imaging showed cortical vein thrombosis with associated venous infarction. Subsequent investigation revealed a strongly positive antinuclear antibody (1 in 22.3 (0–5.5)).

On admission her antimitochondrial and antismooth muscle antibodies. Her thrombophilia screen was strongly positive antinuclear antibody (1 in 22.3 (0–5.5)).

The patient described fulfills the criteria for a diagnosis of primary antiphospholipid syndrome. While there is no histological proof that her pancreatitis was due to vasoocclusive thromboembolism, several facts make this the likely explanation. The recurrent episodes in the absence of another cause, the proven cerebral thromboembolism at the time of her second attack of pancreatitis, and her positive anticardiolipin antibodies are highly suggestive that thromboembolism of her pancreatic blood vessels was indeed the cause of her pancreatitis.

I suggest that the investigation of patients with idiopathic pancreatitis should include checking their antiphospholipid antibodies.

H L Spencer

Correspondence to: Dr H L Spencer, Sheffield Teaching Hospitals, Herries Rd, Sheffield, UK; happyhal@cheerful.com

References


Author’s reply

Autoimmune pancreatitis is a recently described clinical entity in which autoimmune mechanisms are involved in the pathogenesis. As Etemad and colleagues described that autoimmunity was one of six risk factors of chronic pancreatitis, autoimmune pancreatitis is not acute but chronic pancreatitis. Patients with autoimmune pancreatitis rarely showed acute attacks of pancreatitis or marked elevation of serum amylase. Although the pancreas of autoimmune pancreatitis is swollen similar to acute pancreatitis on ultrasound and computed tomography, it is induced by dense lymphoplasmacytic infiltration with fibrosis.

Obliterated phlebitis throughout the pancreas is one of the characteristic pathological findings of autoimmune pancreatitis. The lumen of the vein was filled with prominent cellular infiltrates and fibrosis. Venous occlusion was not due to thromboembolism but to phlebitis. Although the role of obliterative phlebitis is unknown in the pathogenesis of autoimmune pancreatitis, many IgG4 positive plasma cells, which might be closely related to pathogenesis, were observed in the obliterated veins. Signs of thrombosis were not observed in any organs of our patients with autoimmune pancreatitis. We think that autoimmune pancreatitis is quite different from the pancreatitis reported by Spencer.

T Kamisawa, N Funata, A Okamoto

Correspondence to: T Kamisawa, Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, 3-18-22 Komagome, Bunkyo-ku, Tokyo 113-8677, Japan; kamisawa-t.k@komagome-hospital.bunkyo.tokyo.jp

Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging

Patients with hepatitis C virus infection who do not respond to treatment with interferon alone or its combination with ribavirin present a serious clinical challenge and there is no clear choice for treatment in these individuals. Earlier studies with antiviral amantidine, which has been used in influenza, had shown promising results. Now, Adinolfi et al (Gut 2003;42:1561–8) have shown 68% end of treatment response with induction therapy using daily interferon for four weeks (and then three injections weekly) in combination with ribavirin and amantidine hydrochloride.

We had used interferon in doses of 3 million units given subcutaneously thrice weekly with ribavirin 800–1200 mg/day and amantidine hydrochloride 100 mg orally twice a day in a small group of chronic hepatitis C patients who had not responded to a combination of interferon and ribavirin. We found a 50% end of treatment response after a treatment period of 12 months (see table 1). Half of the patients showed no effect on alanine aminotransferase or hepatitis C virus RNA, and in these patients treatment was discontinued after three months.

There are reports of good results with the use of amantidine in combination with interferon. Therefore, although the mechanism of action of amantidine in this setting is unclear, it is becoming obvious that there is an encouraging situation for these hard to treat patients and there may be light at the end of the tunnel. Due to lack of major sponsorship for amantidine from a large
Who should perform endoscopic procedures?

We read with great interest the report of Small et al on upper gastrointestinal endoscopy performed by nurses (Gut 2003;52:1090–4). This work showed a limited experience with specific endoscopy trained nurses that had no significant effect on diagnostic yield, patient discomfort, or patient satisfaction compared with medical staff. Many experiences, some of them mentioned in this report, have shown that nurses can successfully perform endoscopic procedures.

Of course, nurses require a training programme, similar to the one usually offered to our residents and trainees. We are certain that specifically trained nurses could also perform liver biopsies, abdominal ultrasound examinations, diagnostic laparoscopies, and some surgical procedures, such as appendectomy or elective cholecystectomy. Any manual (surgical or endoscopic) procedure may be learnt by anyone, medical or non-medical, in common with many other forms of manual labour or craftsmanship. Frequently, and not so long ago, GPs performed some surgical procedures, such as caesarean section and appendectomy, and barbers once performed surgery. This could be the first step towards a better clinical practice, defining indications for different medical procedures, limiting costs in the many other aspects of endoscopy and gastroenterology, and trying to perform our specific role, nurse or medical, as scientifically based and accurate as possible.

E Redondo-Cerezo, J García-Cano
Digestive Service, Unidad de Endoscopias, Hospital General Virgen de la Luz, Cuenca, Spain
Correspondence to: Dr E Redondo-Cerezo, Servicio de Aparato Digestivo, Hospital General Virgen de la Luz, C/Hermandad de Donantes de Sangre 1 Cuenca 16002, Spain; eredondoc@yahoo.es

The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis

Early diagnosis to distinguish between malignant pancreatic tumours and chronic pancreatitis is still difficult, despite significant progress in imaging techniques. Moreover, patients with chronic pancreatitis have a higher risk of pancreatic cancer development.

The study of Malik et al (Gut 2002;51:849–52) clearly confirms these difficulties, independently of rigorous selection criteria of patients with chronic pancreatitis. To exclude the possibility that chronic pancreatitis may be caused by early potentially premalignant lesions, the authors eliminated from their investigations even patients with chronic pancreatitis in whom pancreatic cancer was recognized during the first two years of follow up.

Several studies indicate the value of circulating tumour marker evaluation as a simple, sensitive, and reliable test facilitating the differential diagnosis between chronic pancreatitis and cancer.1 2 To improve the effectiveness of serological diagnosis of patients with pancreatic cancer, different tumour markers have been assessed, including CEA, CA 242, CA 50, and CA 72-4.3 4 However, the sensitivity and specificity of these markers appeared to be insufficient for differentiation of pancreatic carcinoma from chronic pancreatitis. In 1996, CAM 17-1 was described as a new useful diagnostic marker in pancreatic carcinoma. It showed a sensitivity similar to that of CA 19-9 but higher specificity, giving only 10% false positive results in patients with chronic pancreatitis.

Tissue polypeptide specific antigen (TPS) is a different type of antigen that does not correlate with tumour mass but reflects tumour proliferative activity.5 Our study revealed that elevated levels of TPS detected preoperatively 100% of patients with pancreatic carcinoma. The introduction of 200 UI as a decision criterion for TPS level allowed an increase in the specificity of this marker to 98% and eliminated all but 2% of the false positive results in patients with chronic pancreatitis. Moreover, TPS is useful for detection of the early stages of clinical advancement of pancreatic carcinoma.

It seems that measurement of TPS, using 200 UI as the cut off value, should facilitate more precise discrimination between the early stages of pancreatic carcinoma and chronic pancreatitis.

A Harlizius-Szymkowa, M Strutyńska-Karpinska
Department of Clinical Immunology, Wroclaw Medical University, Mikulczycza-Rodeckie, 77, Wroclaw 50-468, Poland
Correspondence to: Professor A Harlizius-Szymkowa; immuno@immuno.am.wroc.pl

References


Table 1 Patients treated with interferon, ribavirin, and amantidine

<table>
<thead>
<tr>
<th>No</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Duration of treatment (months)</th>
<th>HCV RNA level (millions)</th>
<th>HCV serotype</th>
<th>Biopsy grade/stage</th>
<th>End of treatment response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>42</td>
<td>M</td>
<td>12</td>
<td>3</td>
<td>2/3</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>2</td>
<td>50</td>
<td>F</td>
<td>3</td>
<td>3</td>
<td>2/3</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>M</td>
<td>12</td>
<td>6.6</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>4</td>
<td>52</td>
<td>F</td>
<td>3</td>
<td>6.9</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>5</td>
<td>61</td>
<td>F</td>
<td>3</td>
<td>6.6</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>6</td>
<td>37</td>
<td>M</td>
<td>12</td>
<td>6.1</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>7</td>
<td>36</td>
<td>M</td>
<td>12</td>
<td>2.4</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>8</td>
<td>50</td>
<td>F</td>
<td>3</td>
<td>0.2</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>9</td>
<td>42</td>
<td>M</td>
<td>12</td>
<td>0.48</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
<tr>
<td>10</td>
<td>51</td>
<td>M</td>
<td>3</td>
<td>5.9</td>
<td>3/2</td>
<td>Clear*</td>
<td>No response</td>
</tr>
</tbody>
</table>

*Normal alanine aminotransferase and undetectable hepatitis C virus (HCV) RNA.

Pharmaceutical company however, it may take a while before this happens.

N Khokhar

Correspondence to: Professor N Khokhar, Division of Gastroenterology, Department of Medicine, Shifa International Hospital and Shifa College of Medicine, Islamabad, Pakistan; drnkholkar@yahoo.com

References


www.gutjnl.com
Small bowel malignancy in coeliac disease

We were interested to read the case report by Rampertab et al on small bowel neoplasia in coeliac disease (Gut 2003; 52:1211–14). The findings are very much in accord with ours from the British Society of Gastroenterology (BSG) National UK Survey published earlier this year. Over a two year period (1998–2000), we collected details of 175 cases of small bowel adenocarcinoma of various aetiologies. Of these cases, 13% were associated with coeliac disease. This is consistent with other studies reporting a higher incidence of small bowel adenocarcinomas being associated with coeliac disease.

Although 13% of small bowel adenocarcinomas being associated with coeliac disease implies that the risk of these cancers in coeliac disease is very high, such an increase translates into a very small absolute life time risk of less than 1% as these tumours are rare and coeliac disease is very common. Nevertheless, we agree that coeliac patients require long term follow up for this and other complications. However, the best means of surveillance needs to be determined.

Of most concern is the long delay in the diagnosis of small bowel adenocarcinoma, irrespective of whether or not coeliac disease is present. This leads to poor survival as 40% have metastasised by the time the diagnosis is made. A high index of suspicion is required by all gastroenterologists for this rare, but eminently treatable, type of adenocarcinoma.
see my novel studies 1 "partially reproduced in patients with decompensated cirrhosis. I disagree with some of the results as the study involves a substantial design, methodological, and analysis problems.

The authors said that advanced cirrhotic patients have "generalised vasodilatation". Vasodilatation also occurs in patients but only in the splanchic and pulmonary beds. Indeed, many studies by me and others have shown vasodilatation in the brachial, femoral, cerebral, and renal territories, especially in advanced cirrhosis. Therefore, I would like to stress the point that with advancing cirrhosis, further activation of the neurohumoral systems occurs, with consequent peripheral vasodilatation. However, blood pooling, particularly in the splanchic bed, lowers systemic vascular resistance.

A major criticism of the study of Vaughan et al is that they measured forearm blood flow (FFB) in only one arm. Changing levels of alertness and external stimuli produce similar fluctuations in blood flow of both arms, and lead to significant misleading alterations in the measured responses if unilateral measurements are used. Thus responses to intra-arterial infusions should have been measured in both arms with the results expressed as ratios of concurrent FFB in the infused and non-infused arms, which the latter serves as a contemporaneous control for the drug effects in the former. Further, FBF ratios are more reproducible than unilateral FBF measurements both at rest and following infusion of vasoconstrictors.

The authors demonstrated a surprising increase in FBF (35–40%) in response to infusion of a locally active dose of the potent vasoconstrictor endothelin-1 (ET-1), which reached its maximum within five minutes from the start. They attributed their finding to enhanced ET-1 receptor mediated vasodilatation. This needs to be tested by selectively blocking ET-1 receptors, using BQ-788. To date, upregulation of ET receptors has been reported in the splanchic and pulmonary vascular beds but not in the forearm. How can the maximum response to the slowly acting ET-1 be reached within five minutes? Also, dose-response curves of the effects of ET-1 and BQ-123 should have been performed.

Other authors, ET receptor mediated responses were unaltered while those mediated by the ET receptor were enhanced in patients with decompensated cirrhosis. Thus one would expect that blocking ET receptors with BQ-123 would allow ET-1 to act unopposed on ET receptors and produce enhanced vasodilatation. However, this was not the case (fig 2 in the article). What adds to my surprise here is that BQ-123 produce enhanced vasodilatation. However, what is the reason behind this?

References


Germline testing of mismatch repair genes is not aided by prescreening tumours for allelic loss

Immunostaining and microsatellite testing of tumours is increasingly being used to guide germline testing in individuals with suspected hereditary non-polyposis colorectal cancer (HNPCC). While the aim of these prescreening tests is to identify the tumour and maximise the chance of identifying a pathogenic germline change, it is clear that neither alone is ideal. In clinical practice, germline testing can often only be justified where an individual has developed a tumour which is microsatellite unstable, and which fails to express a mismatch repair protein. Clearly, this approach is imperfect as not all pathogenic germline mutations are associated with failure of expression of the mismatch repair proteins. The aim of this pilot study was to retrospectively assess the utility of loss of heterozygosity studies studying in the predicted mismatch repair gene.

Seven individuals with germline mutations in hMSH2 were identified from the family cancer clinic at St Vincent’s Hospital, Sydney. The tumours from each of these individuals were microsatellite unstable and failed to express hMSH2, but demonstrated normal expression of hMLH1. For loss of heterozygosity (LOH) analysis, we used microsatellite markers D1S180 and D1S235 (for Exon1), D1S25, PM1S1, D2S118, and D2S155 (for PM1S1), D2S21153, D2S2156, D2S2292, D2S2369, and D2S378 (for hMSH2 and hMLH1) and D2S1447 and D3S3685 (for hMLH1). Only heterozygous loci were regarded as informative and LOH was scored when there was a major reduction (at least 50%) or total loss of one allele in the tumour compared to normal tissues.

Of the seven tumours examined in this study, six showed allelic loss of hMSH2, suggesting that the residual normal allele was silenced by LOH (fig 1). In five tumours, allelic loss of hMSH2 occurred in association with LOH in at least one other mismatch repair gene. Only one tumour had retained heterozygosity at all assessable loci, possibly indicating that a mutation had caused the second hit in this tumour.

Allelic loss of hMSH2 often occurs in association with germline mutations but it is clear that loss of the other mismatch repair genes is also a frequent finding. Screening tumours for LOH should not be employed to select patients for mutation analysis of mismatch repair genes. The use of immunohistochemistry and microsatellite testing remain the best available prescreening tools.
Mild respiratory distress after wireless capsule endoscopy

A 74 year old male patient was seen in our clinic for chronic diarrhoea. Duodenal biopsies revealed the presence of coeliac disease; upper and lower endoscopies were otherwise unremarkable. As he also presented with marked anaemia and weight loss, he underwent wireless capsule endoscopy (M2A capsule; Given Imaging) in order to exclude additional small bowel pathology.

On the second day after application of the capsule (and before analysis of the pictures), he complained of mild respiratory distress while walking, which had started “right after swallowing the capsule”. Physical examination revealed quiet inspiratory and expiratory wheezing, most audible over the central part of the right lung. A chest x-ray was obtained (fig 1) which showed aspiration of the video capsule into the right main bronchus. The patient made an uneventful recovery.

He had a history of ankylosing spondylitis with involvement of the cervical spine. Although he reported no symptoms of dysphagia and recalled swallowing the capsule as uneventful, it may be possible that the cervical spine disease contributed to aspiration of the capsule.

To the best of our knowledge, this is the first published case of aspiration of an M2A capsule since this diagnostic method has become available to general clinical practice. It underlines the recommendations of the manufacturer for cautious use in patients with known or possible swallowing disorders (http://www.givenimaging.com).

Late development of cholangiocarcinoma after hepaticojejunostomy due to ampullary carcinoma

We read with great interest the article by Bettigchart et al (Gut 2002;50:128–9) which found an increase in cholangiocarcinoma incidence after biliary-enteric drainage for benign disease.

In their hypothesis, changes in biliary epithelium were induced by toxic carcinogens due to reflux of intestinal contents and bile stasis. However, this chronic irritation and carcinogenesis of the biliary mucosa after biliary-enteric anastomosis has not been reported after surgery for malignant disease. We present a case of a 65 year old woman who developed a cholangiocarcinoma eight years after choledochojunostomy for an ampullary carcinoma, stage I. The patient was referred to our department because of obstructive jaundice and cholangitis. Computed tomography scan showed that the patient was disease free. Percutaneous transhepatic cholangiography showed biliary-enteric anastomosis stricture and a diffuse biliary stenosis.

Figure 1 Chest x-ray showing aspiration of the video capsule into the right main bronchus (Courtesy of Professor G Kauffmann, Heidelberg, Germany).

Figure 1 Anastomosis stricture and diffuse biliary stenosis. Cholangiocarcinoma (arrow) on the right hepatic duct can be seen.
Adoptive transfer of genetic susceptibility to Crohn’s disease

We read with interest the stimulating case report on fulminant Crohn’s colitis following allogeneic bone marrow transplantation by Sonwalkar et al (Gut 2003;52:1518–21) and the respective editorial. The authors and the editorialists hypothesised on whether the colitis might be ascribed to the adoptive transfer of stem cells displaying genetic alterations which are associated with Crohn’s disease. However, the ileal sparing disease localisation and course of the colitis which finally necessitated urgent colectomy is rather unusual for Crohn’s disease. In addition, the genetic mismatch between donor and recipient is hardly compatible with the outlined hypothesis.

According to the cited study by Lesage and colleagues, the allele difference at position –15 of the TATA box polymorphism of the NOD2 gene is not regarded as “a disease causing mutation”. In line with this concept is the fact that the donor and his first degree relatives did not suffer from Crohn’s disease. Apart from this observation, the authors did not describe in detail which particular genetic mutations or polymorphisms differed between the donor and recipient. However, some of the described genes are simply not associated with inflammatory bowel disease. As shown by some of the authors and ourselves, polymorphisms in the MICB gene (which is not situated within the HLA class III but the HLA class I region) are not associated with Crohn’s disease. The same holds true for polymorphisms of the HSP70 gene which were weakly associated with a more severe course of Crohn’s disease in Japanese patients but not with the disease itself. To test all relevant of our knowledge, data on possible associations between mutations of the LMP2, LMP7, and NOTCH1 gene and Crohn’s disease are completely lacking. In conclusion, at best only an extremely weak genetic predisposition can be extracted from the extensive genotyping and thus the postulated transfer of genetic susceptibility remains highly speculative.

The increased incidence of inflammatory bowel disease in patients with comitant immune defects and the recently described increased adherence of bacteria to the intestinal mucosa, which might particularly be facilitated in the presence of mutated NOD2 protein, suggest that the initial event in the complex pathophysiological process in Crohn’s disease is compatible with impaired mucosal clearing function which precedes an excessively large T cell driven immunological activity. This hypothesis is further sustained by various genetically engineered animal models which are protected from the development of enterocolitis under germ free conditions, and therapeutic approaches, such as the use of immunostimulatory substances or mesalazine (full text see Folwaczny and colleagues’). Thus a complementary explanation for the described phenomenon might be the persistent immunosuppressive therapy the donor had received.

C Folwaczny, J Glas, T Mussack, H P Török
Klinikum Innenstadt, Ludwig-Maximilians University, Munich, Germany

Correspondence to: Dr C Folwaczny; Christian.Folwaczny@medinn.med.uni-muenchen.de

References


Self Assessment Colour Review of Hepatobiliary Medicine


Roger Chapman and Henry Bodenheimer have produced a useful addition to the libraries of gastroenterologists with an interest in liver disease. Hepatobiliary Medicine provides 180 questions and answers in 190 pages covering a wide range of hepatobiliary problems. The book will fit in a white coat pocket and is printed on high quality glossy paper. The questions comprise case histories illustrated with laboratory test results and photographs of histology and imaging investigations. Unfortunately, the reproduction does not allow readers to recognise some of the histological and imaging abnormalities referred to in the text, but most can be discerned with the benefit of hindsight (and the answers). The authors have done an excellent job in assembling a diverse collection of cases with relevant images and laboratory data. The questions are presented on one side of the page and the answers are on the reverse, allowing the reader to formulate their own responses without “cheating”.

The subject matter of the book encompasses the full range of liver diseases, including a fair smattering of rarities that are only likely to be encountered more than once by specialist hepatologists. Indeed, the content of some of the cases will test experts. Hepatobiliary Medicine fulfils the remit of the series, as declared in the book’s header, to help readers “learn, revise, reinforce”. Inclusion of a number of paediatric cases will be particularly helpful to adult gastroenterologists/hepatologists who are occasionally asked to see paediatric cases.

The authors have included an index and a list of cases classified by diagnosis. This is extremely useful when using the book for revision or reinforcement and the classification of cases reveals some surprising choices of emphasis. Eight questions on primary sclerosing cholangitis, seven on Wilson’s disease, and one on fatty liver disease hardly reflects the distribution of cases that the general gastroenterologist might encounter but the selection of cases will educate and inform, and the choices reflect the difficulty of diagnostic conundrums rather than disease prevalence.

Publication of this short textbook is timely with the growth of hepatology as a subspeciality and the shortening of training programmes reducing the opportunities for trainees to “learn by osmosis” from case based experience. This book will be particularly useful for trainees in gastroenterology and hepatology.

However, there are a few caveats and some things that could have been improved. The book Hepatobiliary Medicine does not claim to be a textbook but the authoritative voice used in the answers carries an air of certainty. In the vast majority of cases, little fault can be found with the information contained in the answers although the level of knowledge assumed by the authors and that offered to the readers is variable. As a result, some of the information contained in the answers is superficial and some is out of date. Inclusion of key references and a recommended reading list would have been helpful. A compact disc or website presenting the photographic images might enhance the visual aspects of the book.

This book will be useful to trainees in gastroenterology and hepatology, to specialists who are asked to consult on difficult hepatobiliary cases, and even to specialist hepatologists seeking reinforcement of problems they rarely encounter. Self Assessment Colour Review of Hepatobiliary Medicine is a useful addition to the gastroenterologist’s library.

W Rosenberg

The Inflammatory Bowel Disease Yearbook 2003


This is the first in a planned yearly series of updates on the latest topics in inflammatory bowel disease clinical practice and research. I was initially sceptical that the hard backed book format could provide a current overview but was pleasantly surprised that the reviews were topical and cited papers from early 2003 (including for example, the natalizumab trial and wireless endoscopy data). These are aimed at the general gastroenterologist, and those with a more in depth clinical or research interest in inflammatory bowel disease.

Six key current areas are reviewed by experts in the field: conventional drug therapy, the newer biological therapies, serodiagnosis, genetics, imaging developments, and...
probiotics. These topics are written by authors expert in the field, and there is little overlap between the chapters—often a problem in the multiauthor format. I would have preferred more detail in a few areas (for example, pharmacology/adverse response prediction with azathioprine) and a bit less in others (for example, some of the genetics chapter is too detailed, and it was not easy to differentiate replicated from preliminary findings). All chapters are well referenced, with good tables and figures of key points providing clarity.

The Yearbook disappeared once from my shelf while I was trying to review it—to provide preparation for a colleague’s brush with the media spotlight—so I would definitely recommend it as a useful update. It might be especially helpful if one had missed out on attending a recent gastroenterology conference. Finally, Remedic might be able to promote the Yearbook with a prize for guessing the nature and relevance of the weird industrial plumbing on the cover.

D van Heel

Fast Facts: Irritable Bowel Syndrome, 2nd edn


Functional gastrointestinal disorders in general, and irritable bowel syndrome in particular, have long been a minefield of misunderstanding and mismanagement which has caused confusion not only to clinicians but also to patients. In recent years, an international working team have attempted to resolve this babel-like tower of confusion by forming the now famous Rome group and producing Rome criteria which have served to harmonise clinical terms and facilitate trials of therapy. However, in general, ex cathedra statements and weighty tomes from the Vatican have been rejected by the famous Rome group and producing Rome criteria which have served to harmonise clinical terms and facilitate trials of therapy. However, in general, ex cathedra statements and weighty tomes from the Vatican have rarely changed the understanding of the gospel for the average cleric or parishioner, and a simpler interpretation is usually required. This little “hymnal” provided by two experienced practitioners with many decades of practical experience and a “cardinal” understanding of the issues of irritable bowel syndrome, now provides just what is necessary to bring the word to the people.

The book’s mission is to review in a simple and balanced way what we know (and what we do not know) about the nature of symptoms, and their causes, and how, in an equally simple and practical way, both the primary care practitioner and patients can help themselves to cope with what is often a disturbing chronic set of problems. Their communication style is clear and concise, and without any tendency to pontificate.

While the target readership is stated to be the “family doctor”, I am sure that it is equally relevant for the gastroenterologist and for the trainee in gastroenterology for whom the standard textbooks on the subject do not offer much practical guidance in the clinic.

Broadsheet reading patients would also benefit from the balanced view provided by the authors and with luck might in turn reduce the ever-increasing bizzare non-orthodox therapies which are now appearing.

The books first edition appeared in 1999, and has now, by popular demand, been republished in an extensively updated version. It clearly reflects current understanding of the condition and provides a balanced and pragmatic view of its management.

In short, an excellent and up-to-date pocket paler for the practitioner.

British Society of Gastroenterology

Paul Brown Travel Fellowships

The Paul Brown Travel Fellowships are awarded by the Endoscopy Committee of the BSPG. They are intended to assist trainee gastroenterologists and established consultants in visits to units outside the United Kingdom for specialist experience and training in endoscopy.

Specialist registrars who have not achieved their CCST are expected to have the approval of their Postgraduate Dean and their Regional Training Director when they apply for a Travel Fellowship. Applicants are expected to provide confirmation that they have been accepted for training in the unit that they wish to visit.

Successful applicants will be expected to provide a brief written report to the Endoscopy Committee of the outcome of their visit.

Application forms are available from the British Society of Gastroenterology Office, 3 St Andrew’s Place, London NW1 4LB. Email: bsg@mailbox.ulc.ac.uk

PET/CT and SPECT/CT Imaging in Medical, Radiation, Surgical and Nuclear Oncology

This continuing medical education programme will take place on 19–22 March 2004 at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Further details: Office of Continuing Medical Education, Johns Hopkins University School of Medicine, Turner 20, 720 Rutland Avenue, Baltimore, Maryland 21205-2195. Tel: +1 410 955 2959; fax: +1 410 955 0807; email: cmnet@jhmi.edu; website: www.hopkinscme.org.

39th Annual Meeting of the European Association for the Study of the Liver

This meeting will be held on 15–19 April 2004 in Berlin, Germany. Further details: Secretariat, c/o Kennes International, 17 rue du Cendrier, PO Box 1726, CH-1211 Geneva, Switzerland. Tel: +41 22 908 0488; fax: +41 22 732 2850; email: info@easl.ch; website: www.easl.ch/easl2004

• Deadline for receipt of abstracts: 16 November 2003
• Deadline for early registration 10 February 2004

14th International Workshop of Digestive Endoscopy, Ultrasonography and Radiology

The 14th International Workshop of Digestive Endoscopy, Ultrasonography and Radiology will be held in Marseille on 27–28 May 2004.

For further information, please contact: Nathalie Fontant, Atelier Phenix, 41 rue Docteur Morru, 13006 — Marseille (tel: (33) 04-91-37-50-83; fax: (33) 04-91-57-15-28; e-mail: nfontant@aphenix.com).

European Postgraduate Gastro-surgical Course 2004

The EPGS at the Academic Medical Center of the University of Amsterdam will be holding the following courses during the year: ‘Benign Hepato-Biliary Disorders’ will be held on 22 & 23 April 2004, ‘Endosonography live in Amsterdam’ will be held on 2, 3 & 4 June 2004, and ‘Update in Colonoscopy’ will be held on 28 & 29 October 2004. For further information, please contact: J Goedkoop (tel: (31) 566 9262; fax: (33) 267 5594; e-mail: j.goedkoop@amc.uva.nl; website: www.epgs.nl).